Phase 3 trials carried out on 2,260 adolescents in the US"demonstrated 100 percent efficacy and robust antibody responses," the companies say.
Phase 3 trials carried out on 2,260 adolescents in the United States "demonstrated 100 percent efficacy and robust antibody responses", the companies said in a statement on Wednesday. A younger cohort of two-to-five year olds are expected to get their first dose next week in the study which will also cover children as young as six months old.Production increase
Çocuklar için gerek var mı?
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: cnnbrk - 🏆 393. / 55 Read more »